Related Experiment Video
Updated: Aug 2, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Therapies for IDH-Mutant Gliomas
Ruham Alshiekh Nasany1, Macarena Ines de la Fuente2
1Upstate University Hospital and Cancer Center, Syracuse, NY, USA.
Purpose Of Review:
Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct type of primary brain tumors with unique characteristics, behavior, and disease outcomes. This article provides a review of standard of care treatment options and innovative, therapeutic approaches that are currently under investigation for these tumors.
Recent Findings:
Extensive pre-clinical data and a variety of clinical studies support targeting IDH mutations in glioma using different mechanisms, which include direct inhibition and immunotherapies that target metabolic and epigenomic vulnerabilities caused by these mutations. IDH mutations have been recognized as an oncogenic driver in gliomas for more than a decade and as a positive prognostic factor influencing the research for new therapeutic methods including IDH inhibitors, DNA repair inhibitors, and immunotherapy.
Insights
Isocitrate dehydrogenase (IDH) mutant gliomas are primary brain tumors. Research is exploring targeted therapies, including IDH inhibitors and immunotherapies, to improve treatment outcomes.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer genetics
Background:
- Isocitrate dehydrogenase (IDH) mutations define a distinct subtype of primary brain tumors.
- These IDH mutant gliomas exhibit unique clinical behaviors and prognoses.
- IDH mutations have been recognized as key oncogenic drivers for over a decade.
Purpose of the Study:
- To review current standard of care treatments for IDH mutant gliomas.
- To explore innovative and investigational therapeutic strategies.
- To highlight emerging approaches targeting IDH mutations.
Main Methods:
- Review of pre-clinical data and clinical studies.
- Analysis of therapeutic mechanisms targeting IDH mutations.
- Examination of metabolic and epigenomic vulnerabilities.
Main Results:
- Targeting IDH mutations shows promise through direct inhibition and immunotherapy.
- IDH mutations are crucial in driving glioma development.
- IDH mutations serve as a positive prognostic factor, guiding therapeutic research.
Conclusions:
- IDH mutant gliomas require specialized treatment approaches.
- Investigational therapies, including IDH inhibitors and immunotherapies, offer new hope.
- Understanding IDH mutations is key to developing effective glioma treatments.
More Related Videos
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
